What you need to know to understand Alexey Navalny, one of Vladimir Putin’s loudest critics
How some North Dakota farmers and two former Cheesecake Factory execs are reinventing casual dining
Campaigns to raise the minimum wage are finally coming to fruition
The Salesforce.com CEO is pushing his fellow tech billionaires into giving back to the city
From the U.S. jobless rate to the ruble to pollution in Beijing, here are 10 key indicators that you'll want to keep an eye on
Irate parents find an "extruding tool" for decorating cakes unsavory
Reward points suffer from inflation, too. Here are three strategies for getting the most out of the points you have, before their value falls
"No place to rage quite like the Kasper Multipurpose Room," one student gripes
The Zappos CEO is spending $350 million to build a startup paradise in downtown Las Vegas. It hasn't been all unicorns and butterflies
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."